Edith Cowan University

Research Online
Research outputs 2014 to 2021
2020

Tropomyosin autoantibodies associated with checkpoint inhibitor
myositis
Pauline Zaenker
Edith Cowan University

David Prentice
Melanie Ziman
Edith Cowan University

Follow this and additional works at: https://ro.ecu.edu.au/ecuworkspost2013
Part of the Medicine and Health Sciences Commons
10.1080/2162402X.2020.1804703
Zaenker, P., Prentice, D., & Ziman, M. (2020) Tropomyosin autoantibodies associated with checkpoint inhibitor
myositis, OncoImmunology, 9(1), Article 1804703.
https://doi.org/10.1080/2162402X.2020.1804703
This Journal Article is posted at Research Online.
https://ro.ecu.edu.au/ecuworkspost2013/8477

OncoImmunology

ISSN: (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/koni20

Tropomyosin autoantibodies associated with
checkpoint inhibitor myositis
Pauline Zaenker , David Prentice & Melanie Ziman
To cite this article: Pauline Zaenker , David Prentice & Melanie Ziman (2020) Tropomyosin
autoantibodies associated with checkpoint inhibitor myositis, OncoImmunology, 9:1, 1804703, DOI:
10.1080/2162402X.2020.1804703
To link to this article: https://doi.org/10.1080/2162402X.2020.1804703

© 2020 The Author(s). Published with
license by Taylor & Francis Group, LLC.

View supplementary material

Published online: 12 Aug 2020.

Submit your article to this journal

Article views: 47

View related articles

View Crossmark data

Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=koni20

ONCOIMMUNOLOGY
2020, VOL. 9, NO. 1, 1–2, 1804703
https://doi.org/10.1080/2162402X.2020.1804703
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ABSTRACT

ARTICLE HISTORY

This brief report details the measurement and identification of IgA antibodies to tropomyosin in a case of
presumed ocular myositis with paraspinal myositis in a patient with metastatic uveal melanoma treated
with checkpoint inhibitors. High-throughput functional protein microarray analysis and pathway analysis
was conducted to identify IgG and IgA antibodies of interest. Antibody levels were compared to generic
antibody screening results and levels of the antibodies in a cohort of melanoma patients without myositis
(n = 100) at baseline prior to undergoing immunotherapy. The finding of specific muscle antibodies in this
clinical case indicates the pathogenic potential of anti-tropomyosin IgA in the development of checkpoint
inhibitor associated myositis and requires further investigation.
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Brief report
We recently reported a case of presumed ocular myositis with
paraspinal myositis in a patient with metastatic uveal mela
noma treated with checkpoint inhibitors Pembrolizumab and
Ipilimumab/Nivolumab.1 Conventional IgG autoantibody
screening in this case was negative (anti-AChR, antiganglioside, myositis specific antibodies and anti-MuSK). The
patient’s level of creatine kinase (2452 U/l) and troponin I (0.36
micrograms/l) was elevated and an MRI of the cervical muscle
was consistent with myositis.
Serum was taken, two days after hospital admission and prior
to steroid and intravenous immunoglobulin infusion that
achieved complete clinical response. Unfortunately, the patient
passed away at 12 months post immunotherapy commencement
due to cerebral metastases and a further trial of radiotherapy and
other checkpoint inhibitors. Retrospective informed consent was
obtained from the legal representative of the deceased and is
available upon request. The serum was analyzed by microarray
for IgG and IgA binding efficiencies (Supplementary Tables 1
and 2, respectively) to greater than 21000 antigens (>81% of the
human proteome) using the HuProtTM microarray (CDI
Laboratories, USA). The sample was probed on the array at
a 1:1000 dilution and analyzed for Z scores, which identified 84
and 172 positive hits (Z score > 3) for IgG and IgA respectively.
Log2 fold changes (log2FC) were calculated by dividing the case
signal intensity for each antigen by the mean case signal intensity
of all antigens or the median signal intensity of all antigens
across the cohort of other metastatic melanoma samples. In
particular, the microarray results demonstrated high levels of
IgA antibodies to tropomyosin (TPM) isoforms 1, 2 and 3 while
IgG antibodies to these antigens were found to be negative.
Tropomyosin 3 is essential for melanoma metastasis, enabling
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pseudopodium and invadopodium formation.2 Sera from
a group of metastatic melanoma patients without myositis
(n = 100) at baseline prior to undergoing immunotherapy who
were also screened on the array (unpublished, Edith Cowan
University Ethics Committee application number 18957) were
negative to these antigens (Figure 1).
The log2 IgA and IgG data for all antigens in this case
study was then uploaded to Advaita Bio’s iPathwayGuide
(http://www.advaitabio.com/ipathwayguide) software to
determine major pathways enriched by the differentially
elevated antibodies (p-value < 0.05 and a |log2FC| > 3.47
(Z score > 3). A detailed description of the pathway analy
sis approach utilized is described elsewhere.3 Using this
software, a total of 97 elevated antibodies were identified
and 19 biological pathways were found to be significantly
impacted, with cardiac muscle contraction, carbon metabo
lism and hypertrophic cardiomyopathy pathways showing
the most significant involvement in the case study’s IgA
binding profile (p = 5.188 x 10−4, p = .004, p = .007,
respectively). Similar to the microarray results, the most
significant identified biological components associated
with the case IgA binding profile, included muscle thin
filament tropomyosin, striated muscle thin filament and
myofilament (p = 7.4 x 10−7, p = 8.1 x 10−5, p = 9.9
x 10−5, respectively).
Myositis is an autoimmune/antibody-mediated condition
and several myositis-related and -associated autoantibodies
have been identified to date.4,5 The regionalization of the
myositis (paraspinal, ocular and myocardial) in this case is
interesting as in a mouse model of muscular dystrophy, dele
tion of a tropomyosin 3 isoform (Tpm3.1) caused muscle
disease in a similar distribution.6 Garaud et al.7 performed
microarray antibody analysis in breast cancer, with sera and
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Figure 1. Comparison of IgA and IgG levels to tropomyosin isoforms 1, 2 and 3 in
the reported clinical case study. IgA levels from the sera of a group of metastatic
melanoma patients without myositis (n = 100) at baseline prior to undergoing
immunotherapy are also illustrated. Levels are presented as Log2 fold changes
(log2FC) and were calculated by dividing the case signal intensity for each antigen
by the mean case signal intensity of all antigens or the median signal intensity of
all antigens across the cohort of other metastatic melanoma samples. The
horizontal line at log2FC = 3.47 represents the cutoff where the case Z score >
3, indicating a positive signal intensity.
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breast tissue displaying high levels of tumor specific IgA to
tumor antigens, including cancer/testis antigen 1B (CTAG1B)
and ankyrin repeat domain 30B like protein (ANKRD30BL).
These were not related to tumor progression or survival. There
was however, a correlation with the development of tertiary
lymphoid structures within the tumor suggesting local IgA
production. B cell infiltration in tumors is rare but B cell
activation does occur in primary, secondary and tertiary lym
phoid structures and antibodies may play a role in tumor
destruction or progression. Whilst IgA is unable to directly
activate the complement pathway, it can do so via the mannose
lectin pathway. It is now recognized that monomeric IgA
opsonised on cell membranes is able to cause apoptosis and
necrosis by binding to the FcαR1 receptor (CD89) on
neutrophils.8 The exact mechanism of subsequent tissue
damage is under debate and a new novel process called tro
goptosis has been suggested.9
In summary, the finding of specific muscle antibodies in this
case may have played a role in the checkpoint induced myositis
and further studies are required to elucidate the pathogenic
potential of anti-tropomyosin IgA antibodies.
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